Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. September 2025 10:00 ET | Quelle: The Wistar Institute

The Wistar Institute Appoints Katherine Aird, Ph.D., to Ellen and Ronald Caplan Cancer Center

Philadelphia, PA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of...
31. März 2021 07:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...
14. Dezember 2017 06:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE

– Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers – KNOXVILLE, TN, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Provectus...